3 completed, 2 withdrawn, 1 terminated, 1 unknown. 3 Phase 4, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Withdrawn 2, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow ioversol: new trials by email Literature Review of ioversol trials Research Report on ioversol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low-acid Contrast Media for Preventing Post ERCP Pancreatitis Ioversol, Iopromide, Iohexol - Post-ERCP Acute Pancreatitis | Completed | Shandong University | 3979 | 2025-08-01 | 2026-02-06 | |
| Serum Thyroid Function After Iodinated Contrast Administration Iodinated contrast agents - Thyroid Dysfunction | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 400 | 2023-02-15 | 2023-05-30 | |
| Pediatric Risk of Hypothyroidism With Iodinated Contrast Media Iohexol, Iodixanol, Iopromide - Hypothyroidism | Phase 4 | Withdrawn | GE Healthcare | 2022-03-01 | 2022-04-20 | |
| Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1) Lipiodol - Knee Osteoarthritis | Phase 1 | Completed | Assistance Publique - Hôpitaux de Paris | 22 | 2021-03-03 | 2023-08-03 |
| Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Dynamic contrast-enhanced computed tomography, Ioversol - Myelodysplastic Syndromes, Leukemia, Myeloid, Acute | Early Phase 1 | Completed | Washington University School of Medicine | 21 | 2014-06-01 | 2015-06-11 |
| Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL - Renal Impairment | Phase 4 | Terminated | Guerbet | 6 | 2009-01-01 | 2019-03-06 |
| Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography Iodixanol, Ioversol, Iopromide - Coronary Artery Disease (CAD), Renal Impairment | Phase 4 | Withdrawn | GE Healthcare | 2006-06-01 | 2019-04-29 |
Renal Insufficiency (2) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Hypothyroidism (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Musculoskeletal Diseases (1) · Myelodysplastic Syndromes (1) · Osteoarthritis, Knee (1)
GE Healthcare (2) · Assistance Publique - Hôpitaux de Paris (1) · Guerbet (1) · Shandong University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Washington University School of Medicine (1)
United States (3) · China (2) · France (1) · Germany (1)
Amanda Cashen, M.D. (1) · Eddie Darton, MD (1) · Johnny Gibbs, Jr., CCRA (1) · Li Yan (1) · Marc MD Sapoval, PhD (1) · Marc Pignot, PhD (1) · Paul F. Sherwin, MD, PhD (1) · Philippe Bourrinet, PharmD (1) · Zuzana Jirakova Trnkova, MD, PhD (1)